Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e009352
DOI: 10.1136/jitc-2024-009352 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.02.2025. Verfasst von Thomas Eigentler und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humbol…. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Skin Neoplasms, Squamous Cell Carcinoma of Head and Neck, Melanoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CureVac.
Abstract (Originalsprache)
Background
CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 in patients with anti-programmed cell death protein-1 (PD-1) therapy-naïve or anti-PD-1 therapy-refractory cutaneous melanoma (cMEL) and in patients with advanced cutaneous squamous cell carcinoma, head and neck squamous cell carcinoma and adenoid cystic carcinoma.
Methods
This open-label, cohort-based, phase I dose escalation study aimed to establish the maximum tolerated dose (MTD), recommended dose (RD), safety and preliminary efficacy of CV8102 as monotherapy or in combination with a PD-1 inhibitor. The preliminary efficacy of the RD was assessed in patients with cMEL in the expansion cohorts.
Results
Between September 2017 and October 2022, 98 patients were enrolled in monotherapy and combination therapy dose escalation and dose expansion cohorts. Two patients in the CV8102 monotherapy dose escalation cohort experienced relevant toxicities at the 900 µg dose level. One patient had Grade 3 aspartate transaminase/alanine aminotransferase elevation which met dose-limiting toxicity (DLT) criteria. Another patient experienced Grade 3 immune-mediated pneumonitis. No DLTs occurred in the combination therapy dose escalation cohort. The MTD was not formally reached and the RD for expansion was 600 µg. Common treatment-emergent adverse events were fever (57%), chills (37%) and fatigue (25%). In the dose escalation part, objective responses occurred in 3/33 patients treated with CV8102 as monotherapy and in 2/25 patients treated with CV8102 plus a PD-1 inhibitor. In the expansion cohorts in patients with anti-PD-1 therapy-refractory melanoma, 0/10 patients treated with CV8102 as monotherapy and 5/30 patients (17%) treated in combination with a PD-1 inhibitor experienced objective responses.
Conclusions
IT CV8102 was generally well tolerated with preliminary signs of efficacy as monotherapy and in combination with a PD-1 inhibitor. Trial registration number NCT03291002 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany thomas.eigentler@cha…
- Faculty of Medicine, University of Tübingen, Tubingen, Germany.
- Oncodermatology and surgical immunology unit, Blokhin Russian Cancer Research Center, Ministry of Health of Russia, Moscow, Russian Federation.
- Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen - European Metropolitan Area of Nürnberg (CCC ER-EMN), Friedrich-Alexander-Universität (FAU), Erlangen, Germany.
- Department of Dermatology & Allergy, LMU University Hospital, LMU Munich, München, Germany.
- University Hospital Erlangen, Erlangen, Bayern, Germany.
Förderung
- CureVac
Zitieren
APA
Eigentler, T., Thomas, I., Samoylenko, I., Erdmann, M., Heinzerling, L., Ochsenreither, S., Krauss, J., Oberoi, A., Robert, C., Lebbe, C., Martin-Liberal, J., Koch, L., Richtig, E., Terheyden, P., Weishaupt, C., Mohr, P., Semiletova, Y., Perez, C. L., Brossart, P., …, & Gnad-Vogt, U. (2025). Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Journal for ImmunoTherapy of Cancer, 13(2), e009352. https://doi.org/10.1136/jitc-2024-009352
Vancouver
Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, et al. Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Journal for ImmunoTherapy of Cancer. 2025;13(2):e009352. doi:10.1136/jitc-2024-009352
BibTeX
@article{Eigentler2025,
author = {Eigentler, Thomas and Thomas, Ioannis and Samoylenko, Igor and Erdmann, Michael and Heinzerling, Lucie and Ochsenreither, Sebastian and Krauss, Jürgen and Oberoi, Arjun and Robert, Caroline and Lebbe, Celeste and Martin-Liberal, Juan and Koch, Lukas and Richtig, Erika and Terheyden, Patrick and Weishaupt, Carsten and Mohr, Peter and Semiletova, Yulia and Perez, Casilda Llacer and Brossart, Peter and Bauernfeind, Franz Georg and Fluck, Michael and Poltoratskiy, Artem and Sekacheva, Marina and Soria, Ainara and Schmitt-Bormann, Beate and Gonzalez, Marina and Heß, Jana and Wengenmayer, Peter and Seibel, Tobias and Koch, Sven D and Quintini, Gianluca and Codó, Paula and Falk, Martin and Schönborn-Kellenberger, Oliver and Gnad-Vogt, Ulrike},
title = {Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {2},
pages = {e009352},
doi = {10.1136/jitc-2024-009352}
}
EUVIMED